Molecure S.A. (WSE: MOC) is a clinical-stage Polish biotechnology firm focused on small molecule therapies targeting unexplored protein and RNA targets. With a proprietary discovery engine and strategic partnerships, including with global pharma, Molecure is advancing programs in oncology, immunology, and respiratory diseases. The company combines internal R&D with open innovation to accelerate drug development. It offers investors high-risk, high-reward exposure to first-in-class therapeutics emerging from European biotech research.
差價合約 (CFD) 是一種複雜的金融工具，利用槓桿交易雖然可能放大收益，但同樣也會加劇虧損風險，導致資金快速流失。數據顯示，82.78% 的散戶投資者在使用該提供商服務進行差價合約交易時出現帳戶虧損。在進行交易之前，請確保您充分了解差價合約的運作機制，並仔細評估自己是否有能力承擔資金虧損的高風險。
評級和評論
評級和評論
